Trials / Withdrawn
WithdrawnNCT03997292
Intravenous Thrombolysis Registry for Acute Ischemic Stroke in China
Intravenous ThrombolysisRegistry for Acute Ischemic Stroke in China
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- General Hospital of Shenyang Military Region · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
To analyze the real situation of intravenous thrombolysis in acute ischemic stroke in China
Detailed description
Compare the efficacy and safety of different thrombolytic drugs; Analysis of patients during hospital treatment of adverse events and complications; Analysis of factors that affect the effectiveness of treatment; Evaluate the pharmacological benefits of different thrombolytic drugs
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alteplase | According to 0.6-0.9mg / kg alteplase (maximum can not exceed 90mg), of which 10% intravenous injection, the remaining 60 minutes intravenous infusion. |
| DRUG | Urokinase | 1.2-1.5 million U dissolved in 100ml sodium chloride injection, 30 minutes intravenously. |
Timeline
- Start date
- 2018-03-01
- Primary completion
- 2020-09-01
- Completion
- 2020-09-01
- First posted
- 2019-06-25
- Last updated
- 2019-06-25
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03997292. Inclusion in this directory is not an endorsement.